Trial · NCT00724893
Results by group240
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 240
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Achieving Viral Response at Any Evaluation Point (Stage 1) | Stage 1 Participants | 685 | participants | ||
| Number of Participants Achieving Viral Response at 12 Weeks After EOT (Stage 1) | Stage 1 Participants | 660 | Participants | ||
| Number of Participants Achieving Sustained Viral Response (SVR) (Stage 1) | Stage 1 Participants | 638 | Participants | ||
| Number of Participants Achieving SVR (Stage 2) | Stage 2 Participants | 468 | participants | ||
| Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2) | Stage 1 Participants | 76 | participants | ||
| Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2) | Stage 2 Participants | 142 | participants | ||
| Number of Participants Achieving Viral Response at Any Evaluation Point, Excluding Participants Who Discontinued Treatment Prior to Early Virologic Response (EVR) Evaluation (Stage 1) | Stage 1 Participants | 685 | Participants | ||
| Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1) | Stage 1 Participants | 660 | Participants | ||
| Number of Participants Achieving SVR, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1) | Stage 1 Participants | 638 | Participants | ||
| The Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1) | Stage 1 Participants | 679 | Participants | ||
| The Number of Participants Achieving SVR Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1) | Stage 1 Participants | 612 | participants | ||
| The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1) | Stage 1 Participants | Genotype 1 (n=757) | 308 | Participants | |
| The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1) | Stage 1 Participants | Genotype 2 (n=172) | 129 | Participants | |
| The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1) | Stage 1 Participants | Genotype 3 (n=348) | 215 | Participants | |
| The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1) | Stage 1 Participants | Genotype 4 (n=21) | 6 | Participants | |
| The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1) | Stage 1 Participants | Genotype 5 (n=0) | 0 | Participants | |
| The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1) | Stage 1 Participants | Genotype 6 (n=2) | 2 | Participants | |
| The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1) | Stage 1 Participants | Genotype unknown (n=2) | 0 | Participants | |
| The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Liver Fibrosis Stage (Stage 1) | Stage 1 Participants | F0 (n=59) | 34 | Participants | |
| The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Liver Fibrosis Stage (Stage 1) | Stage 1 Participants | F1 (n=159) | 89 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00724893/results